COVID-19, community trials, and inclusion.

Gill, Paramjit S; Poduval, Shoba; Thakur, Jarnail S; Iqbal, Romaina

Gill, Paramjit S; Poduval, Shoba; Thakur, Jarnail S; Iqbal, Romaina.

Afiliación

Gill PS; Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK. Electronic address: p.gill.1@warwick.ac.uk.
Poduval S; UCL eHealth Unit, Department of Primary Care and Population Health, University College London, London, UK.
Thakur JS; Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Iqbal R; Department of Community Health Sciences, Aga Khan University. Karachi, Pakistan.

Lancet ; 397(10279): 1036-1037, 2021 03 20.

Article en En | MEDLINE | ID: mdl-33743853

Asunto(s)

Azitromicina; Tratamiento Farmacológico de COVID-19; Humanos; SARS-CoV-2; Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azitromicina / Tratamiento Farmacológico de COVID-19 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google